

# Index

<b>1. Introduction</b>	<b>1</b>
<b>2. Basics and Methods</b>	<b>3</b>
2.1 Imaging of neurofunctions with positron emission tomography (PET)	3
2.2 Steps of radioligand development	5
2.2.1 Preceding considerations	6
2.2.2 Selection and production of short-lived positron emitting radionuclides especially fluorine-18	7
2.2.3 Development of labelling methods with fluorine-18	9
2.2.4 Special methods in n.c.a. $^{18}\text{F}$ -fluorination	12
2.2.5 Pharmacological evaluation of radioligands for the central nervous system	19
2.3 Dopamine receptors and ligands	24
2.3.1 Subtypes of dopamine receptors – the D <sub>4</sub> receptor	24
2.3.2 Dopamine D <sub>4</sub> receptor subtype-selective ligands	27
2.4 Lipophilicity – A key property for radioligands	32
<b>3. Aims and Scope</b>	<b>37</b>
<b>4. Synthesis and <math>^{18}\text{F}</math>-labelling of FAUC 316</b>	<b>39</b>
4.1 Syntheses of standard and precursor compounds	40
4.1.1 Formation of 2-carboxylic indole <i>via</i> palladium mediated intramolecular coupling	41
4.1.2 Formation of 2-carboxylic indole by intramolecular reductive amination	43
4.1.3 Reduction of 5-cyano-2-carboxyindole ester	44
4.1.4 Syntheses of iodonium precursors	46
4.2 Radiosynthesis of $[^{18}\text{F}]$ FAUC 316	47
4.2.1 Synthesis of 4- $[^{18}\text{F}]$ fluorobromobenzene and 4- $[^{18}\text{F}]$ fluoroiodo-benzene	47
4.2.2 Piperidine and 1-methylpiperazine as model compounds for a radioactive palladium-catalyzed Buchwald-Hartwig cross-coupling	49
4.2.3 Direct Buchwald-Hartwig coupling with 1-benzyl-2-(piperazine-1-yl-methyl)-1 <i>H</i> -indole-5-carbonitrile	52
4.2.4 Synthesis of $[^{18}\text{F}]$ FAUC 316 <i>via</i> 4- $[^{18}\text{F}]$ fluorophenylpiperazine	53
4.2.5 Purification and isolation of $[^{18}\text{F}]$ FAUC 316	58
4.3 Pharmacological evaluation of $[^{18}\text{F}]$ FAUC 316	63
4.4 Interim summary	64

<b>5. Synthesis, <sup>18</sup>F-labelling and preclinical evaluation of benzodioxine derivatives</b>	<b>66</b>
5.1 Synthesis of benzodioxine standard and precursor compounds for <sup>18</sup> F-labelling	67
5.2 Receptor binding and intrinsic affinities	71
5.3 Radiosynthesis of benzodioxine derivatives	75
5.3.1 Direct n.c.a. <sup>18</sup> F-labelling of benzodioxine derivatives	75
5.3.2 Build-up synthesis of benzodioxine derivatives by reductive amination	77
5.3.3 Comparison of <sup>18</sup> F-labelling methods for benzodioxine derivatives	82
5.4 Pharmacological evaluation of <sup>18</sup> F-labelled benzodioxine derivatives as D <sub>4</sub> ligands	84
5.4.1 Lipophilicity	84
5.4.2 Autoradiography	85
5.4.3 Biodistribution and <i>in vivo</i> stability	88
5.5 Interim summary	92
<b>6. Experimental</b>	<b>95</b>
6.1 Materials, chromatographic and spectrometric procedures	95
6.2 Synthesis of [ <sup>18</sup> F]FAUC 316	96
6.2.1 Syntheses of precursor and standard compounds	96
6.2.2 Radiosyntheses	108
6.3 Synthesis of benzodioxine derivatives	111
6.3.1 Syntheses of precursor- and standard compounds	111
6.3.2 Radiosyntheses	120
6.3.3 Radioanalytical methods	123
6.4 Pharmacology	131
6.4.1 Determination of partition coefficients	131
6.4.2 Animals	131
6.4.3 <i>In vitro</i> autoradiography of rat and mouse brain slices	132
6.4.4 <i>Ex vivo</i> biodistribution in mouse model	132
6.4.5 <i>In vivo</i> stability of [ <sup>18</sup> F]33e	132
6.4.6 Staining of brain slices by cresyl violet	133
<b>7. Summary and Outlook</b>	<b>135</b>
<b>8. Literature</b>	<b>141</b>